Cornercap Investment Counsel Inc. decreased its position in shares of The Pennant Group, Inc. (NASDAQ:PNTG - Free Report) by 53.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 15,522 shares of the company's stock after selling 17,733 shares during the period. Cornercap Investment Counsel Inc. owned approximately 0.05% of The Pennant Group worth $554,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Covestor Ltd increased its holdings in shares of The Pennant Group by 3,805.6% during the first quarter. Covestor Ltd now owns 1,406 shares of the company's stock worth $28,000 after purchasing an additional 1,370 shares during the period. USA Financial Formulas acquired a new position in The Pennant Group in the 3rd quarter valued at $121,000. Acadian Asset Management LLC bought a new stake in shares of The Pennant Group during the 1st quarter valued at $218,000. Bailard Inc. acquired a new stake in shares of The Pennant Group during the 2nd quarter worth $253,000. Finally, Summit Global Investments bought a new position in shares of The Pennant Group in the third quarter worth $254,000. Institutional investors and hedge funds own 85.88% of the company's stock.
The Pennant Group Price Performance
NASDAQ:PNTG traded down $0.47 on Friday, hitting $31.43. The company had a trading volume of 188,160 shares, compared to its average volume of 244,589. The firm has a 50 day moving average of $33.76 and a two-hundred day moving average of $28.98. The stock has a market capitalization of $1.08 billion, a price-to-earnings ratio of 46.22, a PEG ratio of 3.22 and a beta of 2.02. The Pennant Group, Inc. has a 52 week low of $12.65 and a 52 week high of $37.13. The company has a current ratio of 1.12, a quick ratio of 1.12 and a debt-to-equity ratio of 0.58.
Analyst Upgrades and Downgrades
PNTG has been the subject of several recent analyst reports. Royal Bank of Canada upped their price objective on shares of The Pennant Group from $26.00 to $38.00 and gave the stock an "outperform" rating in a research report on Wednesday, October 23rd. Stephens reiterated an "overweight" rating and set a $40.00 price target on shares of The Pennant Group in a research report on Wednesday, October 9th. Oppenheimer upped their target price on The Pennant Group from $34.00 to $37.00 and gave the stock an "outperform" rating in a research note on Friday, November 8th. Finally, Truist Financial lifted their price target on The Pennant Group from $34.00 to $38.00 and gave the company a "hold" rating in a research note on Monday, October 7th.
Check Out Our Latest Report on The Pennant Group
The Pennant Group Profile
(
Free Report)
The Pennant Group, Inc provides healthcare services in the United States. It operates in two segments, Home Health and Hospice Services, and Senior Living Services. The company offers home health services, including clinical services, such as nursing, speech, occupational and physical therapy, medical social work, and home health aide services; and hospice services comprising clinical care, education, and counseling services for the physical, spiritual, and psychosocial needs of terminally ill patients and their families.
See Also
Before you consider The Pennant Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and The Pennant Group wasn't on the list.
While The Pennant Group currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.